Rubius Therapeutics Net Income

Rubius Therapeutics (RUBY) currently reports a net income of $-230M as of December 2022. That compares with $-200M in the prior-year period — down 18.9% year over year. That is below the Healthcare sector average of $82B. Use the charts on this page to explore Rubius Therapeutics's net income history and peer comparisons.

Rubius Therapeutics's net income decreased from $-200M to $-230M — a 18.9% year-over-year decrease (period ending December 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Rubius Therapeutics's net income of $-230M is lower than the Healthcare sector average of $82B. That is roughly 100.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Rubius Therapeutics reported $-230M in net income as of December 2022. That compares with $-200M in the prior-year period — down 18.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $-230M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $82B. From there, open related valuation or income-statement pages for Rubius Therapeutics, and consider following RUBY for alerts when major investors trade the stock.